KMTS
BEARISH
$17.87
Live
Kestra Medical Technologies, Ltd. · NASDAQ
Target $28.0
(+56.7%)
$13.25
52W Range
$30.0
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 13, 2026
Market cap
$1.04B
P/E
N/A
ROE
-92.7%
Profit margin
-173.0%
Debt/Equity
0.16
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
KMTS exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating poor operational health and financial instability. Despite strong top-line revenue growth of 62.7% and a high current ratio of 7.32, the company suffers from deep negative profit margins (-172.99%) and a complete lack of positive earnings. The disconnect between the 'Strong Buy' analyst consensus and the actual technical trend (0/100) and bearish insider selling suggests a significant valuation bubble or over-optimism regarding future scaling.
Key Strengths
Strong YoY revenue growth of 62.70%
Excellent short-term liquidity (Current Ratio 7.32)
Healthy Gross Margin of 48.75% suggesting product viability
Low Debt-to-Equity ratio (0.16)
Improving EPS trend with recent quarterly beats
Key Risks
Critical operational failure indicated by Piotroski F-Score of 1/9
Severe negative profitability (Profit Margin -172.99%)
Strong bearish technical trend with consistent price declines
Aggressive insider selling by the CEO and General Counsel
High valuation relative to sales (P/S 12.46) for a non-profitable entity
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
22
Weak
20
65
15
10
0
AI Verdict
High Risk / Speculative
Key drivers: Piotroski F-Score 1/9, Negative Profitability, Bearish Technicals, Insider Selling
Confidence
90%
Value
20/100
Ref P/E, PEG, Graham Number
Positives
- Low Debt/Equity
Watchpoints
- P/S of 12.46 is excessive for current margins
- Negative Forward P/E
- No Graham Number available due to lack of earnings
Future
65/100
Ref Growth rates
Positives
- 62.7% Revenue Growth
- Positive EPS growth trend (+66.1% YoY)
Watchpoints
- High burn rate
- Unproven path to profitability
Past
15/100
Ref Historical trends
Positives
- Recent earnings surprises are positive
Watchpoints
- 1Y Change -26.2%
- 1M Change -19.3%
- Consistent downward price trajectory
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- High Current Ratio (7.32)
Watchpoints
- Piotroski F-Score 1/9 (Weak)
- ROE of -92.65%
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 Dividend Strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$17.87
Analyst Target
$28.0
Upside/Downside
+56.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for KMTS and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
KMTS
Kestra Medical Technologies, Ltd.
Primary
|
-18.2% | -18.2% | -26.2% | -18.8% | -19.3% | -9.9% |
|
AKTS
Aktis Oncology, Inc.
Peer
|
-15.2% | -15.2% | -15.2% | -15.2% | +5.2% | +1.0% |
|
ABCL
AbCellera Biologics Inc.
Peer
|
-90.7% | -53.9% | +45.4% | -21.9% | +11.5% | +1.2% |
|
ASTH
Astrana Health, Inc.
Peer
|
-19.7% | -41.8% | -41.4% | -36.4% | -7.6% | +2.4% |
|
CLOV
Clover Health Investments, Corp.
Peer
|
-78.5% | +126.7% | -40.8% | -29.6% | -5.0% | +8.0% |
KMT
Kestra Medical Technologies, Ltd.
Primary
5Y
-18.2%
3Y
-18.2%
1Y
-26.2%
6M
-18.8%
1M
-19.3%
1W
-9.9%
AKT
Aktis Oncology, Inc.
Peer
5Y
-15.2%
3Y
-15.2%
1Y
-15.2%
6M
-15.2%
1M
+5.2%
1W
+1.0%
ABC
AbCellera Biologics Inc.
Peer
5Y
-90.7%
3Y
-53.9%
1Y
+45.4%
6M
-21.9%
1M
+11.5%
1W
+1.2%
AST
Astrana Health, Inc.
Peer
5Y
-19.7%
3Y
-41.8%
1Y
-41.4%
6M
-36.4%
1M
-7.6%
1W
+2.4%
CLO
Clover Health Investments, Corp.
Peer
5Y
-78.5%
3Y
+126.7%
1Y
-40.8%
6M
-29.6%
1M
-5.0%
1W
+8.0%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-8.35
PEG Ratio
N/A
P/B Ratio
3.62
P/S Ratio
12.46
EV/Revenue
9.54
EV/EBITDA
-5.9
Market Cap
$1.04B
Profitability
Profit margins and return metrics
Profit Margin
-172.99%
Operating Margin
-141.6%
Gross Margin
48.75%
ROE
-92.65%
ROA
-36.84%
Growth
Revenue and earnings growth rates
Revenue Growth
+62.7%
Earnings Growth
N/A
Q/Q Revenue Growth
+62.7%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.16
Low debt
Current Ratio
7.32
Strong
Quick Ratio
7.08
Excellent
Cash/Share
$4.99
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q1 2026
Revenue
$0.0B
Gross Margin
52.6%
Op. Margin
-141.6%
Net Margin
-139.2%
Total Assets
$0.4B
Liabilities
$0.1B
Equity
$0.3B
Debt/Equity
0.32x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
154%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-07-27
$N/A
2026-03-17
$-0.4
+32.6% surprise
2025-12-11
$-0.45
+19.8% surprise
2025-09-11
$-0.36
+53.8% surprise
Healthcare Sector Comparison
Comparing KMTS against 291 companies in the Healthcare sector
(20 bullish, 99 neutral, 172 bearish)
Return on Equity (ROE)
-92.65%
This Stock
vs
-49.88%
Sector Avg
+85.8%
(Excellent)
Profit Margin
-172.99%
This Stock
vs
-9.43%
Sector Avg
+1733.7%
(Superior)
Debt to Equity
0.16
This Stock
vs
3.74
Sector Avg
-95.7%
(Less Debt)
Revenue Growth
62.7%
This Stock
vs
80.78%
Sector Avg
-22.4%
(Slower)
Current Ratio
7.32
This Stock
vs
3.72
Sector Avg
+96.7%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
KMTS
Kestra Medical Technologies, Ltd.
|
BEARISH | $1.04B | - | -92.7% | -173.0% | $17.87 | |
|
AKTS
Aktis Oncology, Inc.
|
BEARISH | $1.05B | - | -26.5% | -% | $18.99 | Compare |
|
ABCL
AbCellera Biologics Inc.
|
NEUTRAL | $1.06B | - | -14.5% | -194.9% | $3.49 | Compare |
|
ASTH
Astrana Health, Inc.
|
BEARISH | $1.02B | 107.0 | 1.8% | 0.3% | $20.33 | Compare |
|
CLOV
Clover Health Investments, Corp.
|
BEARISH | $996.87M | - | -26.3% | -4.4% | $1.9 | Compare |
KMTS
Kestra Medical...
BEARISH
Mkt Cap
$1.0B
P/E
-
ROE
-92.7%
Price
$17.87
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-26 | COHEN RAYMOND W | Director | Purchase | 10,000 | $199,800 |
| 2026-03-17 | WEBSTER BRIAN DANIEL | Chief Executive Officer | Sale | 15,000 | $304,124 |
| 2026-03-11 | REILLY KEVIN C | Director | Stock Award | 8,300 | - |
| 2026-02-17 | WEBSTER BRIAN DANIEL | Chief Executive Officer | Sale | 15,000 | $384,020 |
| 2026-01-15 | WEBSTER BRIAN DANIEL | Chief Executive Officer | Sale | 15,000 | $342,024 |
| 2025-12-29 | WEBSTER BRIAN DANIEL | Chief Executive Officer | Sale | 15,000 | $398,847 |
| 2025-12-29 | UMBERGER TRACI S | General Counsel | Sale | 10,500 | $280,201 |
| 2025-12-03 | MORAN TIMOTHY P. | Officer | Stock Award | 19,557 | - |
COHEN RAYMOND W
Director
2026-03-26
10,000 shares
·
$199,800
WEBSTER BRIAN DANIEL
Chief Executive Officer
2026-03-17
15,000 shares
·
$304,124
REILLY KEVIN C
Director
2026-03-11
8,300 shares
WEBSTER BRIAN DANIEL
Chief Executive Officer
2026-02-17
15,000 shares
·
$384,020
WEBSTER BRIAN DANIEL
Chief Executive Officer
2026-01-15
15,000 shares
·
$342,024
WEBSTER BRIAN DANIEL
Chief Executive Officer
2025-12-29
15,000 shares
·
$398,847
UMBERGER TRACI S
General Counsel
2025-12-29
10,500 shares
·
$280,201
MORAN TIMOTHY P.
Officer
2025-12-03
19,557 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
7 analysts
Goldman Sachs
2026-04-09
Neutral
Neutral
BTIG
2026-04-07
Buy
Buy
BTIG
2026-03-25
Buy
Buy
BTIG
2026-03-18
Buy
Buy
Goldman Sachs
2025-12-15
Neutral
Neutral
Wells Fargo
2025-12-12
Overweight
Overweight
Piper Sandler
2025-12-12
Overweight
Overweight
BTIG
2025-11-18
Buy
Past News Coverage
Recent headlines mentioning KMTS from our newsroom.
Newest → oldest
No matching news yet.